Sarepta Therapeutics (NASDAQ:SRPT) Reaches New 12-Month Low After Analyst Downgrade

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) reached a new 52-week low during mid-day trading on Monday after Deutsche Bank Aktiengesellschaft lowered their price target on the stock from $50.00 to $25.00. Deutsche Bank Aktiengesellschaft currently has a hold rating on the stock. Sarepta Therapeutics traded as low as $18.66 and last traded at $18.84, with a volume of 12623383 shares changing hands. The stock had previously closed at $36.18.

Other equities analysts have also issued reports about the stock. Morgan Stanley reiterated an “equal weight” rating and set a $40.00 target price (down from $113.00) on shares of Sarepta Therapeutics in a report on Monday. Needham & Company LLC reduced their price target on shares of Sarepta Therapeutics from $125.00 to $50.00 and set a “buy” rating for the company in a research report on Monday. Cantor Fitzgerald reissued a “neutral” rating on shares of Sarepta Therapeutics in a research report on Monday. BMO Capital Markets downgraded shares of Sarepta Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $120.00 to $70.00 in a research report on Monday. Finally, Scotiabank raised shares of Sarepta Therapeutics from a “sector perform” rating to a “sector outperform” rating and set a $80.00 price target for the company in a research report on Friday, June 6th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $74.13.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Inspire Investing LLC bought a new position in Sarepta Therapeutics in the 1st quarter worth $967,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Sarepta Therapeutics by 54.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 463,342 shares of the biotechnology company’s stock valued at $29,570,000 after purchasing an additional 164,041 shares during the period. United Services Automobile Association bought a new stake in Sarepta Therapeutics during the 1st quarter valued at approximately $436,000. Great Lakes Advisors LLC bought a new stake in Sarepta Therapeutics during the 1st quarter valued at approximately $224,000. Finally, Scientech Research LLC bought a new stake in Sarepta Therapeutics during the 1st quarter valued at approximately $968,000. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Price Performance

The firm has a 50 day moving average of $45.00 and a 200-day moving average of $84.80. The company has a market cap of $2.12 billion, a P/E ratio of -8.01 and a beta of 0.61. The company has a current ratio of 4.02, a quick ratio of 2.46 and a debt-to-equity ratio of 1.00.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing the consensus estimate of $2.20 by ($5.62). The company had revenue of $744.86 million during the quarter, compared to analysts’ expectations of $685.75 million. Sarepta Therapeutics had a negative return on equity of 14.88% and a negative net margin of 11.12%. The firm’s revenue for the quarter was up 80.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.73 EPS. On average, equities research analysts predict that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.